Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the fixed-dose (prasugrel 10 mg/d vs. 5
mg/d) vs. phenotype (platlet function test by VerifyNow P2Y12 assay)-based prasugrel dose
adjustment can match therapeutic zone of platelet reactivity in PCI-treated Asians with acute
coronary syndrome